![]() Five-year pooled OS rates were 13.4% versus 2.6%, respectively 5-year PFS rates were 8.0% versus 0%, respectively. Exploratory landmark analyses were investigated.Īfter the minimum follow-up of 64.2 and 64.5 months for CheckMate 017 and 057, respectively, 50 nivolumab-treated patients and nine docetaxel-treated patients were alive. The primary end point for both trials was OS secondary end points included progression-free survival (PFS) and safety. Patients (N = 854 CheckMate 017/057 pooled) with advanced NSCLC, ECOG PS ≤ 1, and progression during or after first-line platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg once every 2 weeks) or docetaxel (75 mg/m 2 once every 3 weeks) until progression or unacceptable toxicity. We report 5-year pooled efficacy and safety from these trials. In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated, advanced squamous and nonsquamous NSCLC, respectively. Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). 28 Johns Hopkins Kimmel Cancer Center, Baltimore, MD.27 Bristol Myers Squibb, Princeton, NJ.26 Universitaetsmedizin Essen und Ruhrlandklinik, Essen, Germany.25 Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN.24 John Paul II Hospital, Kraków, Poland.23 UT Southwestern Medical Center, Dallas, TX.22 Robert Bosch Cancer Center, Gerlingen, Germany.20 Aix Marseille University, CNRS, INSERM, CRCM, APHM, Marseille, France.19 Fundacion Jimenez Diaz, IIS-FJD Madrid, Spain.18 Oncology Hematology Care, Inc, Cincinnati, OH.17 Hospital Universitario Virgen Del Rocio, Sevilla, Spain.16 Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.15 Duke University Medical Center, Durham, NC.14 Instituto Nazionale per Lo Studio e La Cura, Milano, Italy.13 Centre Georges-François Leclerc, Dijon, France. ![]() 12 Provincial Center of Oncology in Gdańsk, Gdańsk, Poland.11 Cross Cancer Institute, Edmonton, AB, Canada.Maria Della Misericordia, Perugia, Italy. 9 Centro de Investigación Clínica Bradford Hill and Centro Internacional de Estudios Clinicos, Santiago, Chile.8 Instituto Nacional De Cancerología, Mexico City, Mexico.7 Maria Sklodowska-Curie Inst of Oncology, Warsaw, Poland.6 Hospital De Madrid, Norte Sanchinarro, Madrid, Spain.5 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.4 University of Washington, Seattle Cancer Care Alliance, Seattle, WA.3 Univeristy of Chicago Medicine and Biologic Sciences Division, Chicago, IL.2 Yale Comprehensive Cancer Center, New Haven, CT.1 Fox Chase Cancer Center, Philadelphia, PA.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |